Cargando…

Genetic testing in children with Brugada syndrome: results from a large prospective registry

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND/INTRODUCTION: A pathogenic/likely pathogenic (P/LP) variant can be found in 20-25% of patients with Brugada syndrome (BrS) and a P/LP variant in SCN5A is associated with a worse prognosis. However, the diagnostic yield and the progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Pannone, L, Osey, R, Gauthey, A, Sorgente, A, Della Rocca, D G, Overeinder, I, Bala, G, Almorad, A, Stroker, E, Sieira, J, La Meir, M, Brugada, P, Chierchia, G B, Van Dooren, S, De Asmundis, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207434/
http://dx.doi.org/10.1093/europace/euad122.267
_version_ 1785046452676853760
author Pannone, L
Osey, R
Gauthey, A
Sorgente, A
Della Rocca, D G
Overeinder, I
Bala, G
Almorad, A
Stroker, E
Sieira, J
La Meir, M
Brugada, P
Chierchia, G B
Van Dooren, S
De Asmundis, C
author_facet Pannone, L
Osey, R
Gauthey, A
Sorgente, A
Della Rocca, D G
Overeinder, I
Bala, G
Almorad, A
Stroker, E
Sieira, J
La Meir, M
Brugada, P
Chierchia, G B
Van Dooren, S
De Asmundis, C
author_sort Pannone, L
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND/INTRODUCTION: A pathogenic/likely pathogenic (P/LP) variant can be found in 20-25% of patients with Brugada syndrome (BrS) and a P/LP variant in SCN5A is associated with a worse prognosis. However, the diagnostic yield and the prognosis of gene testing in pediatric BrS syndrome is unclear. PURPOSE: The aim of this study is to define the diagnostic yield of SCN5A gene testing with ACMG standardized variant classification in a large cohort of pediatric BrS. Furthermore, a correlation between the clinical outcomes and the genetic background of children with BrS in comparison with adult BrS is aimed. METHODS: All consecutive patients diagnosed with BrS, between 1992 and 2022 were enrolled in a prospective monocentric registry. Inclusion criteria were: 1) BrS diagnosis; 2) Genetic analysis for SCN5A gene and 3) classification of gene variants following current ACMG guidelines. Pediatric patients were defined if ≤ 12 years of age. The primary endpoint was ventricular arrhythmias (VA) occurrence, defined as documented SCD, aborted SCD, ventricular tachycardia or ventricular fibrillation or appropriate ICD intervention. RESULTS: A total of 500 BrS patients were included, 41 pediatric patients and 459 adult patients. Among children with BrS, 19 patients (46.3%) had a P/LP variant (P+) in SCN5A gene. No P/LP variants could be identified in 22 (53.7%) pediatric patients (P-). After a mean follow-up of 140.2 months, 3 children (7.3%) experienced a VA, treated with appropriate ICD shock. Inappropriate shocks occurred in 3 pediatric patients (7.3%). At survival analysis, P- pediatric patients had higher VA free survival during the follow-up, compared with P+ pediatric patients (Log-Rank p=0.021), Figure 1. There was no difference in VA free survival between pediatric and adult BrS patients both without (P-), (Log-Rank p=0.19) and with (P+) a P/LP variant (Log-Rank p=0.91), Figure 2. CONCLUSION: In a large BrS cohort, the diagnostic yield for SCN5A P/LP variants in the pediatric population is 46.3%. P+ children with BrS have a worse arrhythmic prognosis. [Figure: see text] [Figure: see text]
format Online
Article
Text
id pubmed-10207434
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102074342023-05-25 Genetic testing in children with Brugada syndrome: results from a large prospective registry Pannone, L Osey, R Gauthey, A Sorgente, A Della Rocca, D G Overeinder, I Bala, G Almorad, A Stroker, E Sieira, J La Meir, M Brugada, P Chierchia, G B Van Dooren, S De Asmundis, C Europace 13.2 - Epidemiology, Prognosis, Outcome FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND/INTRODUCTION: A pathogenic/likely pathogenic (P/LP) variant can be found in 20-25% of patients with Brugada syndrome (BrS) and a P/LP variant in SCN5A is associated with a worse prognosis. However, the diagnostic yield and the prognosis of gene testing in pediatric BrS syndrome is unclear. PURPOSE: The aim of this study is to define the diagnostic yield of SCN5A gene testing with ACMG standardized variant classification in a large cohort of pediatric BrS. Furthermore, a correlation between the clinical outcomes and the genetic background of children with BrS in comparison with adult BrS is aimed. METHODS: All consecutive patients diagnosed with BrS, between 1992 and 2022 were enrolled in a prospective monocentric registry. Inclusion criteria were: 1) BrS diagnosis; 2) Genetic analysis for SCN5A gene and 3) classification of gene variants following current ACMG guidelines. Pediatric patients were defined if ≤ 12 years of age. The primary endpoint was ventricular arrhythmias (VA) occurrence, defined as documented SCD, aborted SCD, ventricular tachycardia or ventricular fibrillation or appropriate ICD intervention. RESULTS: A total of 500 BrS patients were included, 41 pediatric patients and 459 adult patients. Among children with BrS, 19 patients (46.3%) had a P/LP variant (P+) in SCN5A gene. No P/LP variants could be identified in 22 (53.7%) pediatric patients (P-). After a mean follow-up of 140.2 months, 3 children (7.3%) experienced a VA, treated with appropriate ICD shock. Inappropriate shocks occurred in 3 pediatric patients (7.3%). At survival analysis, P- pediatric patients had higher VA free survival during the follow-up, compared with P+ pediatric patients (Log-Rank p=0.021), Figure 1. There was no difference in VA free survival between pediatric and adult BrS patients both without (P-), (Log-Rank p=0.19) and with (P+) a P/LP variant (Log-Rank p=0.91), Figure 2. CONCLUSION: In a large BrS cohort, the diagnostic yield for SCN5A P/LP variants in the pediatric population is 46.3%. P+ children with BrS have a worse arrhythmic prognosis. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207434/ http://dx.doi.org/10.1093/europace/euad122.267 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 13.2 - Epidemiology, Prognosis, Outcome
Pannone, L
Osey, R
Gauthey, A
Sorgente, A
Della Rocca, D G
Overeinder, I
Bala, G
Almorad, A
Stroker, E
Sieira, J
La Meir, M
Brugada, P
Chierchia, G B
Van Dooren, S
De Asmundis, C
Genetic testing in children with Brugada syndrome: results from a large prospective registry
title Genetic testing in children with Brugada syndrome: results from a large prospective registry
title_full Genetic testing in children with Brugada syndrome: results from a large prospective registry
title_fullStr Genetic testing in children with Brugada syndrome: results from a large prospective registry
title_full_unstemmed Genetic testing in children with Brugada syndrome: results from a large prospective registry
title_short Genetic testing in children with Brugada syndrome: results from a large prospective registry
title_sort genetic testing in children with brugada syndrome: results from a large prospective registry
topic 13.2 - Epidemiology, Prognosis, Outcome
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207434/
http://dx.doi.org/10.1093/europace/euad122.267
work_keys_str_mv AT pannonel genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT oseyr genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT gautheya genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT sorgentea genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT dellaroccadg genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT overeinderi genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT balag genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT almorada genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT strokere genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT sieiraj genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT lameirm genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT brugadap genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT chierchiagb genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT vandoorens genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry
AT deasmundisc genetictestinginchildrenwithbrugadasyndromeresultsfromalargeprospectiveregistry